3 Hidden Small-Caps Quietly Winning the Defense Tech Arms Race

Everyone's busy arguing about Nvidia and mortgage rates at 7.58% (a nearly three-year high, per CNBC). Meanwhile, a few genuinely interesting small-caps are doing something unusual: building real businesses in growth niches with almost zero retail attention. Here are three that showed up in the sentiment data with interesting signals and zero hype tax built into the price.

$KTOS (Kratos Defense and Security Solutions) is one of the few pure-play drone and unmanned systems companies on the public market, with a market cap sitting comfortably under $5B. Kratos builds autonomous drones, satellite communications gear, and microwave electronics for the US military. With the US-Iran conflict dominating headlines and defense budgets expanding on both sides of the Atlantic, the catalyst here is structural: DoD procurement cycles for low-cost attritable drones are accelerating, and Kratos has been a preferred vendor. The bear case is real, margins are thin and the company burns cash during development phases. But the bull case is that its Valkyrie drone program keeps landing test contracts that tend to convert. Watch for any new DoD contract announcements in Q4.

$SPSC (SPS Commerce) is about as unsexy as it gets: cloud-based supply chain management software for retailers and their suppliers, headquartered in Minneapolis. Market cap is around $3B. Most people have never heard of it, which is exactly the point. SPS Commerce runs a recurring-revenue network model where every new retailer it onboards creates a pull effect that forces suppliers to join too. Revenue retention rates are consistently above 100%, meaning existing customers spend more every year. In a high-rate environment where growth stocks get punished, SPS trades at a discount to peers simply because no one bothers to look. The catalyst is any acceleration in retail digitization spending or a mid-market M&A wave that brings new supplier networks onto its platform.

$GKOS (Glaukos Corporation) is a medical device company focused entirely on glaucoma treatment, specifically minimally invasive surgical implants that reduce eye pressure without the misery of daily eye drops. Market cap is around $4B. The company just launched its iDose TR sustained-release drug delivery implant, which is a genuinely differentiated product in a $4B-plus global glaucoma market that is chronically underserved. The bear case: it is pre-profitability on the new product line and cash burn matters when the 10-year yield sits at 5.24%. The bull case: if iDose adoption accelerates through ophthalmology networks, the revenue curve goes non-linear fast. Glaucoma affects roughly 80 million people globally and surgical penetration is still in the single digits.

None of these are lottery tickets. They are boring, specific, and operating in niches where the competition is either fragmented or asleep. Which, in a market where everyone is crowded into the same seven mega-caps, might actually be the most interesting place to be.